Founded in February 2024 by CEO Sébastien Lasnier, SYNAPTYS Neuroscience is a biotech company based in the scientific cluster of the Saclay plateau (near Paris). It is supported by IncubAlliance, the deeptech incubator of Paris-Saclay, and Genopole through its Upscale Bio program.
SYNAPTYS is pioneering a new therapeutic approach that could transform the lives of patients living with Alzheimer’s disease.
DESCRIPTIF DE L’ACTIVITÉ
SYNAPTYS neuroscience is developing SYS-0108, the first Neuro-Synergistic Conjugate for Alzheimer’s disease — a disruptive, patented innovation inspired by combination strategies used in oncology.
SYS-0108 combines two existing molecules — Memantine and Cholecalciferol — both of which have demonstrated positive effects. Using an AI-inspired boosting method, the action of Memantine is amplified to enhance its neuroprotective efficacy.
SYS-0108 is based on four inseparable, integrated processes:
- Innovative composition: Memantine + Cholecalciferol
- Targeted brain delivery: precise binding to key receptors involved in Alzheimer’s (NMDA and VDR)
- Chronopharmacology: time-specific administration to enable optimal neuroprotective effects
- Optimized dosing: experimentally validated ratio for long-lasting efficacy
SYS-0108 acts at the core of Alzheimer’s pathophysiology to slow disease progression, mitigate cognitive decline, and preserve brain function.
A rapidly growing market: By 2050, over 150 million people are expected to be affected worldwide, representing a $20+ billion/year market, with families eagerly awaiting truly effective treatments.
Currently in preclinical development, SYNAPTYS Neuroscience is actively seeking academic and financial partners to accelerate clinical advancement.
